Jeff Marc Goldberg - 29 Nov 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Reporting relationship: President and CEO, Director
Issuer ticker: SYRE
Reported as of: 29 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Dec 2022, 19:47:37 UTC
Source filing: View source filing
Reporting owner signature: /s/ James Kastenmayer, by power of attorney

Key filing fact

Jeff Marc Goldberg filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 01 Dec 2022.

Key facts

This page summarizes Jeff Marc Goldberg's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Dec 2022, 19:47.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGLE transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,884,838
Change %
Price: $0.000000
Shares after: 1,884,838
Date: 29 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,884,838
Exercise price: $1.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable as to 1/4 of the total award on November 29, 2023, and an additional 1/48 of the award will vest monthly thereafter until the option is 100% vested on November 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.